ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
63.347,28
-0,85%
Brent Oil
82,765
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Verastem Inc (VSTM)

  7. Verastem Inc (VSTM) Notícias

VSTM

Verastem (VSTM)

Verastem Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VSTM
DataHoraFonteTítuloCódigoCompanhia
18/04/202417:05Business WireVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerNASDAQ:VSTMVerastem Inc
04/04/202408:30Business WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
18/03/202408:00Business WireGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
14/03/202417:05Business WireVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesNASDAQ:VSTMVerastem Inc
11/03/202418:07Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:VSTMVerastem Inc
11/03/202408:30Business WireVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsNASDAQ:VSTMVerastem Inc
05/03/202419:27Business WireVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
05/03/202418:30Business WireVerastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024NASDAQ:VSTMVerastem Inc
08/02/202418:22Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:VSTMVerastem Inc
02/02/202411:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VSTMVerastem Inc
29/01/202418:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
29/01/202409:00Business WireVerastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven CancersNASDAQ:VSTMVerastem Inc
18/01/202418:00Business WireVerastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)NASDAQ:VSTMVerastem Inc
11/01/202409:00Business WireVerastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:VSTMVerastem Inc
09/01/202418:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
19/12/202318:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VSTMVerastem Inc
18/12/202309:00Business WireVerastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet TherapeuticsNASDAQ:VSTMVerastem Inc
13/12/202309:00Business WireVerastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
08/12/202318:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VSTMVerastem Inc
21/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VSTMVerastem Inc
13/11/202309:00Business WireNew Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment ApproachNASDAQ:VSTMVerastem Inc
08/11/202319:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VSTMVerastem Inc
08/11/202318:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VSTMVerastem Inc
08/11/202318:12Business WireVerastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:VSTMVerastem Inc
07/11/202309:00Business WireFirst-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
06/11/202309:00Business WireVerastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient PopulationNASDAQ:VSTMVerastem Inc
26/10/202317:05Business WireVerastem Oncology Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:VSTMVerastem Inc
14/10/202313:30Business WireVerastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung CancerNASDAQ:VSTMVerastem Inc
28/09/202315:15Business WireVerastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development SummitNASDAQ:VSTMVerastem Inc
05/09/202308:00Business WireVerastem Oncology to Participate in Upcoming Investor ConferencesNASDAQ:VSTMVerastem Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VSTM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZUL4
AZUL PN
BOV
GOLL4
GOL PN
BOV
HETA4
HERCULES PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados